Website News and Research

RSS

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

Inspire Pharmaceuticals, Inc. announced today financial results for the fourth quarter and year ended December 31, 2009, reporting a net loss of $2.6 million or ($0.03) per share for the fourth quarter and a net loss of $40.0 million or ($0.60) per share for the full year.

4 Mar 2010

APTA: CMS announces dates for holding claims

(U.S. Physical Therapy) The American Physical Therapy Association (APTA) reported on its website (APTA.org) on Friday, February 26, 2010 that “The Centers for Medicare and Medicaid Services (CMS) announced that it will hold claims for the first 10 business days of March. The hold will apply to claims with dates of service of March 1, 2010 through March 12, 2010. Claims with dates of service of January 1, 2010-February 28, 2010 will continue to be paid based on the 0% update approved by Congress.

2 Mar 2010

Sigma-Aldrich unveils new Sigma Life Science brand and website platform

Sigma-Aldrich® today unveiled its new Sigma® Life Science brand and website platform, designed to elevate the Company's current focus on biology and provide a single destination where researchers can access deep biological knowledge and market-leading products and technologies.

2 Mar 2010

Ban Asbestos Now campaign launched to educate public on the dangers of asbestos inhalation

"Ban Asbestos Now," a national campaign to build awareness of the continued use of asbestos in the United States, launched today to educate the public on the dangers of asbestos inhalation and urge Americans to pressure U.S. lawmakers to finally ban this toxic and often deadly substance. It is considered "the largest manmade public health crisis in history" according to the Asbestos Disease Awareness Organization.

2 Mar 2010

PARI Respiratory Equipment launches new aerosol delivery system

Today, PARI Respiratory Equipment launched their newest aerosol delivery system, the Vios. Paired with PARI's gold standard reusable nebulizers, Vios delivers fast treatments, small particle size, and high respirable drug dose to the lungs. Vios also features an extended warranty and Timestrip, an easy to use reminder for patients to replace their nebulizer every six months.

1 Mar 2010

First Personal Injury praises HSE's workplace safety campaign

The latest phase of the campaign aims to raise awareness of the potential dangers of trips and falls in the workplace and features some graphic and hard hitting posters. The posters, typically featuring alarming images of workers 'shattering' upon impact following a fall, also feature safety information targeted at reducing such accidents.

1 Mar 2010

NuVasive: Aetna changes spinal surgery policy to include coverage for XLIF procedure

NuVasive, Inc., a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Aetna changed its spinal surgery policy to include coverage for the eXtreme Lateral Interbody Fusion, or XLIF procedure, published on February 26, 2010, a reversal from its previous policy that labeled XLIF as experimental and investigational.

27 Feb 2010

Aetna.com: Most visited health insurance website

The recently redesigned Aetna.com is a hit with web surfers, who made it the most visited website among health insurers in the fourth quarter of 2009. In fact, 20 percent of Americans who visited a health insurance website during the quarter visited an Aetna site, according to “The Online Health Insurance Landscape,” an independent online audience measurement of health insurance websites recently released by comScore.

27 Feb 2010

Cell Therapeutics files 2009 Annual Report on Form 10-K

Cell Therapeutics, Inc. today announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2009. This filing is available for review on CTI's website at www.CellTherapeutics.com, or on the Securities and Exchange Commission's website at www.sec.gov.

27 Feb 2010

Synta Pharmaceuticals presents preclinical and clinical data of Hsp90 inhibitor STA-9090

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Geoffrey I. Shapiro of Dana-Farber Cancer Institute, presented preclinical and clinical data on STA-9090, a potent second-generation Hsp90 inhibitor, at IASLC (International Association for the Study of Lung Cancer) 10th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting in Santa Monica, CA.

27 Feb 2010

Vion Pharmaceuticals' Onrigin SPA: FDA responds

VION PHARMACEUTICALS, INC. announced today that it had received a response from the U.S. Food and Drug Administration on a Special Protocol Assessment for its oncology therapeutic Onrigin™ (laromustine) Injection.

26 Feb 2010

AST now offers programs and services to treat children with developmental disorders

Autism Spectrum Therapies, an agency providing comprehensive autism services throughout Southern California, is expanding its services to include speech and language programs and occupational therapy, in addition to behavior therapy. The focus of the new services will be early intervention for children from infancy to age three and developmental catch-up for young children who have fallen behind in any developmental area.

26 Feb 2010

MiMedx Group completes corporate and technology branding initiative

MiMedx Group, Inc. announced today that it has completed its corporate and technology branding initiative. In concert with its branding initiative, the Company also announced that it has recently launched an updated website.

25 Feb 2010

Campaign to stop sale of electronic mosquito repellents by major airlines begins to bear fruit

A campaign to stop the sale of electronic mosquito repellents by major airlines is beginning to bear fruit with the immediate withdrawal of the products from KLM flights. The issue being that these electronic repellents, sold to airline passengers, many on their way to malaria endemic countries, just don't work.

25 Feb 2010

"Hope – It's In Our Genes" rare disease campaign slogan translated into multiple international languages and Braille

The Global Genes Project (www.globalgenesproject.org), today announced that its rare disease campaign slogan, "Hope – It's In Our Genes™," has been translated into multiple international languages and Braille by rare disease patient advocates and supporters from around the world. The translation of this slogan unifies the rare disease community and global network under one banner.

25 Feb 2010

Dangers of steroid abuse: Steroids.com gone live

Effective today, Steroids.com has gone live under new ownership with the primary goal to educate youths about the dangers of steroid abuse. Backed by the legal team at Womack & Associates of Houston, Texas, Steroids.com aims to become the de-facto informational website related to all things steroids.

25 Feb 2010

Study demonstrates Prochymal treamtent is safe for cardiac patients

“Patients receiving Prochymal did better than those receiving only standard-of-care,” said Dr. Hare, lead author of the JACC publication.

25 Feb 2010

Toys"R"Us fundraising campaign to benefit Autism Speaks

Toys"R"Us, U.S. today announced that its fundraising campaign to benefit Autism Speaks will begin Sunday, February 28 and continue through Friday, April 30. Throughout the campaign, monetary donations will be collected at all Toys"R"Us and Babies"R"Us stores and online at Toysrus.com/AutismSpeaks.

25 Feb 2010

Skills for Health launches new online resources to explore benefits of health sector apprenticeships

New online resources to help employers, learners and training providers explore the benefits of health sector apprenticeships are launched today.

25 Feb 2010

NIPTRC and partners announce development of new imaging process for proton beam therapy in cancer

Scientists and researchers from the Northern Illinois Proton Treatment and Research Center (NIPTRC) and Northern Illinois University along with their partners are developing a new imaging process using a proton beam that they believe will be a major medical breakthrough in the delivery of proton beam therapy for cancer patients.

25 Feb 2010

Website News and Research

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

APTA: CMS announces dates for holding claims

Sigma-Aldrich unveils new Sigma Life Science brand and website platform

Ban Asbestos Now campaign launched to educate public on the dangers of asbestos inhalation

PARI Respiratory Equipment launches new aerosol delivery system

First Personal Injury praises HSE's workplace safety campaign

NuVasive: Aetna changes spinal surgery policy to include coverage for XLIF procedure

Aetna.com: Most visited health insurance website

Cell Therapeutics files 2009 Annual Report on Form 10-K

Synta Pharmaceuticals presents preclinical and clinical data of Hsp90 inhibitor STA-9090

Vion Pharmaceuticals' Onrigin SPA: FDA responds

AST now offers programs and services to treat children with developmental disorders

MiMedx Group completes corporate and technology branding initiative

Campaign to stop sale of electronic mosquito repellents by major airlines begins to bear fruit

"Hope – It's In Our Genes" rare disease campaign slogan translated into multiple international languages and Braille

Dangers of steroid abuse: Steroids.com gone live

Study demonstrates Prochymal treamtent is safe for cardiac patients

Toys"R"Us fundraising campaign to benefit Autism Speaks

Skills for Health launches new online resources to explore benefits of health sector apprenticeships

NIPTRC and partners announce development of new imaging process for proton beam therapy in cancer

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News